Pinebridge Investments L.P. Boosts Stock Position in Repligen Co. (NASDAQ:RGEN)

Pinebridge Investments L.P. grew its stake in shares of Repligen Co. (NASDAQ:RGEN) by 223.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,090 shares of the biotechnology company’s stock after acquiring an additional 22,170 shares during the period. Pinebridge Investments L.P.’s holdings in Repligen were worth $2,758,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Royce & Associates LP raised its position in shares of Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after buying an additional 145 shares in the last quarter. Falcon Point Capital LLC raised its position in shares of Repligen by 2.5% in the first quarter. Falcon Point Capital LLC now owns 6,922 shares of the biotechnology company’s stock worth $409,000 after buying an additional 167 shares in the last quarter. Summit Creek Advisors LLC raised its position in shares of Repligen by 0.3% in the second quarter. Summit Creek Advisors LLC now owns 84,537 shares of the biotechnology company’s stock worth $7,266,000 after buying an additional 230 shares in the last quarter. Pitcairn Co. raised its position in shares of Repligen by 7.0% in the second quarter. Pitcairn Co. now owns 3,769 shares of the biotechnology company’s stock worth $324,000 after buying an additional 245 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in shares of Repligen by 1.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 15,117 shares of the biotechnology company’s stock worth $893,000 after buying an additional 273 shares in the last quarter. Hedge funds and other institutional investors own 88.66% of the company’s stock.

In other news, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the transaction, the director now directly owns 118,329 shares of the company’s stock, valued at $9,152,748.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Anthony Hunt sold 12,094 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $82.40, for a total value of $996,545.60. Following the transaction, the chief executive officer now directly owns 210,976 shares in the company, valued at $17,384,422.40. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.

A number of equities research analysts have weighed in on the company. BidaskClub downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $110.00 price target on shares of Repligen in a research report on Monday, August 12th. Stephens restated an “overweight” rating and set a $110.00 price target on shares of Repligen in a research report on Thursday, August 22nd. Craig Hallum raised their price target on Repligen from $80.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Finally, Zacks Investment Research downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Repligen currently has an average rating of “Buy” and an average target price of $101.17.

NASDAQ RGEN traded up $0.73 during trading hours on Friday, reaching $79.74. 449,168 shares of the stock traded hands, compared to its average volume of 596,959. The stock has a 50 day simple moving average of $91.13 and a two-hundred day simple moving average of $74.53. Repligen Co. has a 1 year low of $48.26 and a 1 year high of $99.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.25 and a quick ratio of 1.88. The company has a market cap of $4.07 billion, a price-to-earnings ratio of 79.01, a price-to-earnings-growth ratio of 4.64 and a beta of 1.16.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.06. Repligen had a return on equity of 6.92% and a net margin of 11.42%. The business had revenue of $70.70 million for the quarter, compared to the consensus estimate of $65.47 million. During the same quarter last year, the business posted $0.14 earnings per share. The company’s revenue for the quarter was up 48.1% on a year-over-year basis. On average, sell-side analysts forecast that Repligen Co. will post 0.97 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.